These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11543683)

  • 1. Identification of alkylidene hydrazides as glucagon receptor antagonists.
    Ling A; Hong Y; Gonzalez J; Gregor V; Polinsky A; Kuki A; Shi S; Teston K; Murphy D; Porter J; Kiel D; Lakis J; Anderes K; May J; Knudsen LB; Lau J
    J Med Chem; 2001 Sep; 44(19):3141-9. PubMed ID: 11543683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human glucagon receptor antagonists based on alkylidene hydrazides.
    Ling A; Plewe M; Gonzalez J; Madsen P; Sams CK; Lau J; Gregor V; Murphy D; Teston K; Kuki A; Shi S; Truesdale L; Kiel D; May J; Lakis J; Anderes K; Iatsimirskaia E; Sidelmann UG; Knudsen LB; Brand CL; Polinsky A
    Bioorg Med Chem Lett; 2002 Feb; 12(4):663-6. PubMed ID: 11844695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel conformationally constrained glucagon receptor antagonist.
    Lee EC; Tu M; Stevens BD; Bian J; Aspnes G; Perreault C; Sammons MF; Wright SW; Litchfield J; Kalgutkar AS; Sharma R; Didiuk MT; Ebner DC; Filipski KJ; Brown J; Atkinson K; Pfefferkorn JA; Guzman-Perez A
    Bioorg Med Chem Lett; 2014 Feb; 24(3):839-44. PubMed ID: 24418771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of furan-2-carbohydrazides as orally active glucagon receptor antagonists.
    Hasegawa F; Niidome K; Migihashi C; Murata M; Negoro T; Matsumoto T; Kato K; Fujii A
    Bioorg Med Chem Lett; 2014 Sep; 24(17):4266-70. PubMed ID: 25127101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide.
    Madsen P; Ling A; Plewe M; Sams CK; Knudsen LB; Sidelmann UG; Ynddal L; Brand CL; Andersen B; Murphy D; Teng M; Truesdale L; Kiel D; May J; Kuki A; Shi S; Johnson MD; Teston KA; Feng J; Lakis J; Anderes K; Gregor V; Lau J
    J Med Chem; 2002 Dec; 45(26):5755-75. PubMed ID: 12477359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New beta-alanine derivatives are orally available glucagon receptor antagonists.
    Lau J; Behrens C; Sidelmann UG; Knudsen LB; Lundt B; Sams C; Ynddal L; Brand CL; Pridal L; Ling A; Kiel D; Plewe M; Shi S; Madsen P
    J Med Chem; 2007 Jan; 50(1):113-28. PubMed ID: 17201415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor.
    Kodra JT; Jørgensen AS; Andersen B; Behrens C; Brand CL; Christensen IT; Guldbrandt M; Jeppesen CB; Knudsen LB; Madsen P; Nishimura E; Sams C; Sidelmann UG; Pedersen RA; Lynn FC; Lau J
    J Med Chem; 2008 Sep; 51(17):5387-96. PubMed ID: 18707090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist.
    DeMong D; Dai X; Hwa J; Miller M; Lin SI; Kang L; Stamford A; Greenlee W; Yu W; Wong M; Lavey B; Kozlowski J; Zhou G; Yang DY; Patel B; Soriano A; Zhai Y; Sondey C; Zhang H; Lachowicz J; Grotz D; Cox K; Morrison R; Andreani T; Cao Y; Liang M; Meng T; McNamara P; Wong J; Bradley P; Feng KI; Belani J; Chen P; Dai P; Gauuan J; Lin P; Zhao H
    J Med Chem; 2014 Mar; 57(6):2601-10. PubMed ID: 24527772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New 2-arylpyrazolo[3,4-c]quinoline derivatives as potent and selective human A3 adenosine receptor antagonists. Synthesis, pharmacological evaluation, and ligand-receptor modeling studies.
    Colotta V; Catarzi D; Varano F; Capelli F; Lenzi O; Filacchioni G; Martini C; Trincavelli L; Ciampi O; Pugliese AM; Pedata F; Schiesaro A; Morizzo E; Moro S
    J Med Chem; 2007 Aug; 50(17):4061-74. PubMed ID: 17665891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of histidine-1 in glucagon action.
    Unson CG; Macdonald D; Merrifield RB
    Arch Biochem Biophys; 1993 Feb; 300(2):747-50. PubMed ID: 8382034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists.
    Dallas-Yang Q; Shen X; Strowski M; Brady E; Saperstein R; Gibson RE; Szalkowski D; Qureshi SA; Candelore MR; Fenyk-Melody JE; Parmee ER; Zhang BB; Jiang G
    Eur J Pharmacol; 2004 Oct; 501(1-3):225-34. PubMed ID: 15464082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and structure-activity relationship of quinuclidine benzamides as agonists of alpha7 nicotinic acetylcholine receptors.
    Bodnar AL; Cortes-Burgos LA; Cook KK; Dinh DM; Groppi VE; Hajos M; Higdon NR; Hoffmann WE; Hurst RS; Myers JK; Rogers BN; Wall TM; Wolfe ML; Wong E
    J Med Chem; 2005 Feb; 48(4):905-8. PubMed ID: 15715459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topographical amino acid substitution in position 10 of glucagon leads to antagonists/partial agonists with greater binding differences.
    Azizeh BY; Shenderovich MD; Trivedi D; Li G; Sturm NS; Hruby VJ
    J Med Chem; 1996 Jun; 39(13):2449-55. PubMed ID: 8691441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oxyntomodulin: a cAMP-dependent stimulus of rat parietal cell function via the receptor for glucagon-like peptide-1 (7-36)NH2.
    Schepp W; Dehne K; Riedel T; Schmidtler J; Schaffer K; Classen M
    Digestion; 1996; 57(6):398-405. PubMed ID: 8913701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships of glucagon-like peptide-1(7-36)amide: insulinotropic activities in perfused rat pancreases, and receptor binding and cyclic AMP production in RINm5F cells.
    Watanabe Y; Kawai K; Ohashi S; Yokota C; Suzuki S; Yamashita K
    J Endocrinol; 1994 Jan; 140(1):45-52. PubMed ID: 8138751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advances in non-peptide glucagon receptor antagonists.
    Madsen P; Brand CL; Holst JJ; Knudsen B
    Curr Pharm Des; 1999 Sep; 5(9):683-691. PubMed ID: 10495358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis of benzamide derivatives as TRPV1 antagonists.
    Shishido Y; Jinno M; Ikeda T; Ito F; Sudo M; Makita N; Ohta A; Iki-Taki A; Ohmi T; Kanai Y; Tamura T; Shimojo M
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1072-8. PubMed ID: 18155908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cloning and expression of canine glucagon receptor and its use to evaluate glucagon receptor antagonists in vitro and in vivo.
    Yang X; Yates ML; Candelore MR; Feeney W; Hora D; Kim RM; Parmee ER; Berger JP; Zhang BB; Qureshi SA
    Eur J Pharmacol; 2007 Jan; 555(1):8-16. PubMed ID: 17140563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis, and evaluation of simple phenol amides as ERRγ agonists.
    Lin H; Doebelin C; Patouret R; Garcia-Ordonez RD; Chang MR; Dharmarajan V; Bayona CR; Cameron MD; Griffin PR; Kamenecka TM
    Bioorg Med Chem Lett; 2018 May; 28(8):1313-1319. PubMed ID: 29548571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of an essential serine residue in glucagon: implication for an active site triad.
    Unson CG; Merrifield RB
    Proc Natl Acad Sci U S A; 1994 Jan; 91(2):454-8. PubMed ID: 8290548
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.